𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

✍ Scribed by Faye M. Johnson; Shruti Agrawal; Howard Burris; Lee Rosen; Navneet Dhillon; David Hong; Anne Blackwood-Chirchir; Feng R. Luo; Oumar Sy; Sanjeev Kaul; Alberto A. Chiappori

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
222 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I and pharmacokinetic study of a s
Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors : The relation between pharmacokinetic property and toxicity
✍ Ruey-Long Hong; Yun-Long Tseng πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

## BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation time and, thereby, higher tumor selectivity and antitumor activity. The stability in plasma is an important consideration in the formulation of clinically useful liposomal drug. A Phase I study o

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and